Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Total Liabilities (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Total Liabilities for 3 consecutive years, with $9.6 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Total Liabilities fell 88.44% year-over-year to $9.6 million, compared with a TTM value of $9.6 million through Sep 2024, down 88.44%, and an annual FY2023 reading of $57.7 million, up 449.86% over the prior year.
  • Total Liabilities was $9.6 million for Q3 2024 at Oramed Pharmaceuticals, up from $8.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $82.7 million in Q3 2023 and bottomed at $5.7 million in Q2 2023.
  • Average Total Liabilities over 3 years is $22.9 million, with a median of $10.0 million recorded in 2022.
  • The sharpest move saw Total Liabilities surged 632.18% in 2023, then tumbled 88.44% in 2024.
  • Year by year, Total Liabilities stood at $10.5 million in 2022, then skyrocketed by 449.86% to $57.7 million in 2023, then crashed by 83.42% to $9.6 million in 2024.
  • Business Quant data shows Total Liabilities for ORMP at $9.6 million in Q3 2024, $8.1 million in Q2 2024, and $37.9 million in Q1 2024.